Seth Forman

5.4k total citations · 4 hit papers
55 papers, 2.3k citations indexed

About

Seth Forman is a scholar working on Dermatology, Immunology and Allergy and Epidemiology. According to data from OpenAlex, Seth Forman has authored 55 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Dermatology, 22 papers in Immunology and Allergy and 12 papers in Epidemiology. Recurrent topics in Seth Forman's work include Dermatology and Skin Diseases (23 papers), Allergic Rhinitis and Sensitization (16 papers) and Food Allergy and Anaphylaxis Research (10 papers). Seth Forman is often cited by papers focused on Dermatology and Skin Diseases (23 papers), Allergic Rhinitis and Sensitization (16 papers) and Food Allergy and Anaphylaxis Research (10 papers). Seth Forman collaborates with scholars based in United States, Canada and Poland. Seth Forman's co-authors include Eric L. Simpson, Jonathan I. Silverberg, Hernán Valdez, Pinaki Biswas, Rodney Sinclair, Thomas Bieber, Ricardo Rojo, Robert Bissonnette, Kim Papp and Jonathan Janes and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Allergy and Clinical Immunology.

In The Last Decade

Seth Forman

48 papers receiving 2.3k citations

Hit Papers

Efficacy and safety of abrocitinib in adults and adolesce... 2018 2026 2020 2023 2020 2021 2018 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    2020 313 citations Eric L. Simpson, Rodney Sinclair et al. profile →
  2. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
    2021 287 citations Eric L. Simpson, Jonathan I. Silverberg et al. profile →
  3. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
    2018 250 citations Emma Guttman‐Yassky, Jonathan I. Silverberg et al. Journal of the American Academy of Dermatology profile →
  4. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
    2021 199 citations Kim Papp, Lawrence F. Eichenfield et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Seth Forman United States 19 1.9k 1.1k 527 444 367 55 2.3k
Katherine C. Pierson United States 13 917 0.5× 123 0.1× 209 0.4× 423 1.0× 1.7k 4.7× 14 2.2k
B. M. Czarnetzki Germany 16 208 0.1× 191 0.2× 137 0.3× 98 0.2× 468 1.3× 49 1.1k
Paola Cordiali‐Fei Italy 21 169 0.1× 72 0.1× 246 0.5× 80 0.2× 353 1.0× 39 1.0k
Piotr Dziunycz Switzerland 22 309 0.2× 83 0.1× 64 0.1× 65 0.1× 416 1.1× 42 1.7k
Mauro Novelli Italy 25 981 0.5× 46 0.0× 118 0.2× 65 0.1× 578 1.6× 77 1.7k
John R. Spaull United Kingdom 14 125 0.1× 123 0.1× 281 0.5× 74 0.2× 134 0.4× 17 878
Stanley Cheuk Sweden 10 421 0.2× 30 0.0× 95 0.2× 151 0.3× 1.1k 3.1× 13 1.4k
Maria Tengvall-Linder Sweden 9 183 0.1× 112 0.1× 54 0.1× 89 0.2× 281 0.8× 10 870
Takeya Adachi Japan 13 254 0.1× 69 0.1× 46 0.1× 51 0.1× 446 1.2× 45 1000
Guillaume Page France 8 100 0.1× 78 0.1× 566 1.1× 40 0.1× 965 2.6× 9 1.5k

Countries citing papers authored by Seth Forman

Since Specialization
Citations

This map shows the geographic impact of Seth Forman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seth Forman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seth Forman more than expected).

Fields of papers citing papers by Seth Forman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seth Forman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seth Forman. The network helps show where Seth Forman may publish in the future.

Co-authorship network of co-authors of Seth Forman

This figure shows the co-authorship network connecting the top 25 collaborators of Seth Forman. A scholar is included among the top collaborators of Seth Forman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seth Forman. Seth Forman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosmarin, David, Amit G. Pandya, Thierry Passeron, et al.. (2025). Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo. Dermatology and Therapy. 15(12). 3703–3716.
2.
Simpson, Eric L., Lawrence F. Eichenfield, Kim Papp, et al.. (2025). Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial. Dermatitis. 37(1). 75–83. 1 indexed citations
3.
Chovatiya, Raj, Seth Forman, Afsáneh Alavi, et al.. (2025). 61888 Bimekizumab efficacy by disease duration in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT. Journal of the American Academy of Dermatology. 93(3). AB135–AB135.
4.
Gold, Linda Stein, Robert Bissonnette, Seth Forman, et al.. (2025). A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis. American Journal of Clinical Dermatology. 26(2). 275–289. 6 indexed citations
5.
Eichenfield, Lawrence F., Linda Stein Gold, Eric L. Simpson, et al.. (2025). Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study. Journal of the American Academy of Dermatology. 93(3). 689–698. 1 indexed citations
6.
Harris, John E., Kim Papp, Khaled Ezzedine, et al.. (2025). Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study. British Journal of Dermatology. 194(3). 591–593. 1 indexed citations
7.
Forman, Seth, Dipak Patel, Alexa B. Kimball, et al.. (2025). A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa. Journal of the American Academy of Dermatology. 94(2). 530–538.
8.
9.
Piliang, Melissa, Charles Lynde, Brett King, et al.. (2024). Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial. Journal of the American Academy of Dermatology. 92(2). 276–284. 5 indexed citations
10.
Senna, Maryanne M., Seth Forman, Lindsey A. Bordone, et al.. (2023). 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study. Journal of the American Academy of Dermatology. 89(3). AB221–AB221. 1 indexed citations
11.
Eichenfield, Lawrence F., Sanela Tarabar, Seth Forman, et al.. (2023). Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis. JAMA Dermatology. 160(2). 156–156. 11 indexed citations
12.
Soung, Jennifer, Vivian Laquer, Seth Forman, et al.. (2023). LB1702 Lebrikizumab does not impact vaccine-induced immune responses: Results from a phase 3 study in adult patients with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology. 143(9). B15–B15. 2 indexed citations
13.
Blauvelt, Andrew, Javier Alonso‐Llamazares, Neal Bhatia, et al.. (2023). Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial. SKIN The Journal of Cutaneous Medicine. 7(2). s196–s196.
14.
Simpson, Eric L., Seth Forman, Jonathan I. Silverberg, et al.. (2021). Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). Journal of the American Academy of Dermatology. 85(1). 62–70. 106 indexed citations
15.
Gottlieb, Alice B., Francisco A. Kerdel, Seth Forman, et al.. (2020). A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain. Journal of Investigative Dermatology. 140(8). 1538–1545.e2. 64 indexed citations
16.
17.
Guttman‐Yassky, Emma, Jonathan I. Silverberg, Osamu Nemoto, et al.. (2018). Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. Journal of the American Academy of Dermatology. 80(4). 913–921.e9. 250 indexed citations breakdown →
18.
Forman, Seth & Robert Brown. (2007). P158-M Expression of c-kit, p-mTOR and p-NFKappaB in Angiolymphoid Hyperplasia with Eosinophilia: Potential for Therapy with Imitanib Mesylate, Rapamycin and Bortezomib. Journal of Biomolecular Techniques JBT. 18(1). 55–55. 1 indexed citations
19.
Forman, Seth, et al.. (2007). Collision tumor composed of Merkel cell carcinoma and lentigo maligna melanoma. Journal of Cutaneous Pathology. 35(2). 203–206. 10 indexed citations
20.
Forman, Seth. (1983). Bravo's Fallout: International Law and Nuclear Pollution in the Pacific. 14(1). 172. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katherine C. Pierson Breakdown of academic impact, for papers by B. M. Czarnetzki Breakdown of academic impact, for papers by Paola Cordiali‐Fei Breakdown of academic impact, for papers by Piotr Dziunycz Breakdown of academic impact, for papers by Mauro Novelli Breakdown of academic impact, for papers by John R. Spaull Breakdown of academic impact, for papers by Stanley Cheuk Breakdown of academic impact, for papers by Maria Tengvall-Linder Breakdown of academic impact, for papers by Takeya Adachi Breakdown of academic impact, for papers by Guillaume Page
Rankless by CCL
2026